108 related articles for article (PubMed ID: 31737207)
1. LncRNA CACS15 accelerates the malignant progression of ovarian cancer through stimulating EZH2-induced inhibition of APC.
Liu Y; Sun J; Yu J; Ge W; Xiao X; Dai S; Xiang Q
Am J Transl Res; 2019; 11(10):6561-6568. PubMed ID: 31737207
[TBL] [Abstract][Full Text] [Related]
2. LINC00702 accelerates the progression of ovarian cancer through interacting with EZH2 to inhibit the transcription of KLF2.
Wang L; Ye TY; Wu H; Chen SY; Weng JR; Xi XW
Eur Rev Med Pharmacol Sci; 2019 Aug; 23(3 Suppl):201-208. PubMed ID: 31389610
[TBL] [Abstract][Full Text] [Related]
3. Long noncoding RNA UFC1 acts as an oncogene via stimulating EZH2-induced inhibition of APC expression in renal cell carcinoma.
Wang J; Liu G
Cell Mol Biol (Noisy-le-grand); 2023 Apr; 69(4):152-156. PubMed ID: 37329532
[TBL] [Abstract][Full Text] [Related]
4. LncRNA DANCR aggravates the progression of ovarian cancer by downregulating UPF1.
Pei CL; Fei KL; Yuan XY; Gong XJ
Eur Rev Med Pharmacol Sci; 2019 Dec; 23(24):10657-10663. PubMed ID: 31858532
[TBL] [Abstract][Full Text] [Related]
5. MiRNA-96 accelerates the malignant progression of ovarian cancer via targeting FOXO3a.
Yang N; Zhang Q; Bi XJ
Eur Rev Med Pharmacol Sci; 2020 Jan; 24(1):65-73. PubMed ID: 31957819
[TBL] [Abstract][Full Text] [Related]
6. The carcinogenic complex lncRNA DUXAP8/EZH2/LSD1 accelerates the proliferation, migration and invasion of colorectal cancer.
Gong A; Huang Z; Ge H; Cai Y; Yang C
J BUON; 2019; 24(5):1830-1836. PubMed ID: 31786844
[TBL] [Abstract][Full Text] [Related]
7. LINC01210 accelerates proliferation, invasion and migration in ovarian cancer through epigenetically downregulating KLF4.
Zhang C; Liu J; Zhang Y; Luo C; Zhu T; Zhang R; Yao R
Biomed Pharmacother; 2019 Nov; 119():109431. PubMed ID: 31514068
[TBL] [Abstract][Full Text] [Related]
8. LncRNA SNHG12 accelerates the progression of ovarian cancer via absorbing miRNA-129 to upregulate SOX4.
Sun D; Fan XH
Eur Rev Med Pharmacol Sci; 2019 Mar; 23(6):2345-2352. PubMed ID: 30964158
[TBL] [Abstract][Full Text] [Related]
9. LINC01308 accelerates the malignant progression of ovarian cancer by binding to miRNA-506.
Zhang YY; Li P; Zhu MZ; Guo Y; Yang J
Eur Rev Med Pharmacol Sci; 2019 Apr; 23(8):3253-3260. PubMed ID: 31081077
[TBL] [Abstract][Full Text] [Related]
10. lncRNA ZEB2-AS1 Aggravates Progression of Non-Small Cell Lung Carcinoma via Suppressing PTEN Level.
Chen X; Wang K
Med Sci Monit; 2019 Nov; 25():8363-8370. PubMed ID: 31695021
[TBL] [Abstract][Full Text] [Related]
11. LINC00460 accelerates progression of ovarian cancer by activating transcriptional factor ZNF703.
Wang X; Gan X; Liu C; Zhang W
Oncol Lett; 2020 Jun; 19(6):4189-4194. PubMed ID: 32382355
[TBL] [Abstract][Full Text] [Related]
12. LncRNA LINC00673 inhibits p53 expression by interacting with EZH2 and DNMT1 in papillary thyroid carcinoma.
Meng XF; Zhao LY; Chu XF
Eur Rev Med Pharmacol Sci; 2019 Mar; 23(5):2075-2083. PubMed ID: 30915752
[TBL] [Abstract][Full Text] [Related]
13. PKMYT1 aggravates the progression of ovarian cancer by targeting SIRT3.
Xuan ZH; Wang HP; Zhang XN; Chen ZX; Zhang HY; Gu MM
Eur Rev Med Pharmacol Sci; 2020 May; 24(10):5259-5266. PubMed ID: 32495859
[TBL] [Abstract][Full Text] [Related]
14. Long non-coding RNA GAS5 inhibits DDP-resistance and tumor progression of epithelial ovarian cancer via GAS5-E2F4-PARP1-MAPK axis.
Long X; Song K; Hu H; Tian Q; Wang W; Dong Q; Yin X; Di W
J Exp Clin Cancer Res; 2019 Aug; 38(1):345. PubMed ID: 31391118
[TBL] [Abstract][Full Text] [Related]
15. Linc-UBC1 stimulates the metastasis and progression of ovarian cancer via downregulating p53 level.
Liu H; Zeng SY; Xie Y; Fei CQ; Sun L
Eur Rev Med Pharmacol Sci; 2020 Feb; 24(3):1054-1061. PubMed ID: 32096175
[TBL] [Abstract][Full Text] [Related]
16. Up-regulation of lncRNA CASC9 promotes esophageal squamous cell carcinoma growth by negatively regulating PDCD4 expression through EZH2.
Wu Y; Hu L; Liang Y; Li J; Wang K; Chen X; Meng H; Guan X; Yang K; Bai Y
Mol Cancer; 2017 Aug; 16(1):150. PubMed ID: 28854977
[TBL] [Abstract][Full Text] [Related]
17. LncRNA DLEU2 aggravates the progression of hepatocellular carcinoma through binding to EZH2.
Guo Y; Bai M; Lin L; Huang J; An Y; Liang L; Liu Y; Huang W
Biomed Pharmacother; 2019 Oct; 118():109272. PubMed ID: 31376657
[TBL] [Abstract][Full Text] [Related]
18. LINC00665 promotes Ovarian Cancer progression through regulating the miRNA-34a-5p/E2F3 axis.
Xu D; Song Q; Liu Y; Chen W; Lu L; Xu M; Fang X; Zhao W; Zhou H
J Cancer; 2021; 12(6):1755-1763. PubMed ID: 33613764
[No Abstract] [Full Text] [Related]
19. EZH2 promotes the expression of LPA1 by mediating microRNA-139 promoter methylation to accelerate the development of ovarian cancer.
Wu D; Wu F; Li B; Huang W; Wang D
Cancer Cell Int; 2020 Nov; 20(1):551. PubMed ID: 33292225
[TBL] [Abstract][Full Text] [Related]
20. lncRNA PVT1 accelerates progression of non-small cell lung cancer via targeting miRNA-526b/EZH2 regulatory loop.
Qiu C; Li S; Sun D; Yang S
Oncol Lett; 2020 Feb; 19(2):1267-1272. PubMed ID: 32002028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
